Allergan plc (NYSE: AGN) is making inroads in the dry eye disease treatment area, paying $50 million upfront to license Mimetogen Pharmaceuticals‘ tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist. Allergan will also fund Phase 3 development of the drug, which has shown the ability to improve patient-reported blurriness and poor vision. The deal bolsters Allergan’s mid- to late-stage pipeline in eye care products.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
